Avizen Biopharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.22 Cr
as on 24-10-2024
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.66 Cr
as on 24-10-2024
- Revenue -15.41%
(FY 2023)
- Profit 7.16%
(FY 2023)
- Ebitda 920.88%
(FY 2023)
- Net Worth -211.47%
(FY 2023)
- Total Assets -0.30%
(FY 2023)
About Avizen Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.22 Cr.
The company currently has active open charges totaling ₹3.66 Cr.
Mahendra Verma, Rajendra Verma, and Sunil Khemani serve as directors at the Company.
- CIN/LLPIN
U24304AS2016PTC017532
- Company No.
017532
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Aug 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Kamrup, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Avizen Biopharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahendra Verma  | Director | 09-Aug-2016 | Current |
| Rajendra Verma | Director | Current | |
| Sunil Khemani | Director | 25-Feb-2017 | Current |
Financial Performance of Avizen Biopharma.
Avizen Biopharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.41% decrease. The company also saw a slight improvement in profitability, with a 7.16% increase in profit. The company's net worth observed a substantial decline by a decrease of 211.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avizen Biopharma?
In 2023, Avizen Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vl Infratech Services Private LimitedActive 13 years 8 monthsMahendra Verma and Rajendra Verma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Dec 2021 | ₹1.85 M | Open |
Others Creation Date: 29 Sep 2020 | ₹3.68 M | Open |
Others Creation Date: 30 Mar 2017 | ₹3.11 Cr | Open |
How Many Employees Work at Avizen Biopharma?
Unlock and access historical data on people associated with Avizen Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avizen Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avizen Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
